Autosomal dominant medullary cystic kidney disease with or without hyperuricemia
MONDO:0008264A genetic kidney disease that causes progressive loss of kidney function caused by mutations in the genes encoding uromodulin (UMOD), hepatocyte nuclear factor-1β (HNF1B), renin (REN), or mucin-1 (MUC1).
Also known as: ADTKD, autosomal dominant interstitial kidney disease, autosomal dominant medullary cystic kidney disease, autosomal dominant medullary cystic kidney disease with or without hyperuricemia, MCKD, autosomal dominant tubulointerstitial kidney disease, medullary cystic disease, medullary cystic kidney disease
8 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New antibody M0324 enters first human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study is testing a new drug called M0324, a bispecific antibody designed to target cancer cells. The trial will look at M0324 alone, with the immunotherapy pembrolizumab, and with chemotherapy in about 77 people with advanced solid tumors that have not responded …
Phase: PHASE1 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Could a diabetes drug protect kidneys in children with genetic disease?
Disease control Recruiting nowThis study tests whether adding dapagliflozin (a diabetes drug) to standard care reduces protein leakage in the urine of children with hereditary kidney diseases. About 44 children will receive either dapagliflozin plus standard care or standard care alone for 12 weeks, then swit…
Phase: PHASE3 • Sponsor: Children's Hospital of Fudan University • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Immune cells tailored to attack lung cancer show promise in early trial
Disease control Recruiting nowThis trial investigates whether specially engineered T cells can safely target and fight lung cancer. Participants have advanced or relapsed lung cancer and receive a single infusion of their own T cells that have been trained to recognize cancer-specific markers. The study aims …
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Engineered immune cells take aim at Hard-to-Treat cervical cancer
Disease control Recruiting nowThis trial investigates whether specially engineered immune cells (CAR-T cells) can safely treat advanced or recurrent cervical cancer. The cells are designed to recognize and attack cancer cells that carry certain markers like GD2 or Mesothelin. The study involves 20 adults with…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC